South Dakota: Market and legal data for the cannabis sector

27th March 2024: US - South Dakota: House Bill (HB) 1125 has been signed by the governor. HB 1125 will prohibit "chemically derived cannabinoids" – which are psychoactive cannabinoids that are changed molecularly through a chemical process (not to include decarboxylation) – from being produced or sold in the state. It will be unlawful to chemically modify or convert industrial hemp, or engage in any process that converts cannabidiol, into delta-8 THC, delta-9 THC, delta-10 THC, or any other tetrahydrocannabinol isomer, analogue, or derivative.
20th March 2024: US - South Dakota: Senate Bill (SB) 43 has been signed by the governor. SB 43 will make minor amendments to the state’s medical cannabis programme by requiring the Department of Health to establish certain penalties for violation of medical cannabis regulation and increasing the maximum amount that the department can charge for registration certificates.
8th March 2024: US - South Dakota: Senate Bill (SB) 117 has been signed by the governor. SB 117 will exclude “industrial hemp stalk bale” from certain requirements and extend the validity of a hemp processor licence to three years.
7th March 2024: US - South Dakota: Senate Bill (SB) 42 has been signed by the governor. SB 42 will make various amendments to the state’s medical cannabis programme, including changes to testing requirements, the allowable amount of medical cannabis that can be dispensed to qualified patients, and the procedure for violations of medical cannabis regulations.
27th February 2024: US - South Dakota: Senate Bill (SB) 117 has been passed by both chambers (the Senate and the House) and now heads to the governor. SB 117 would exclude “industrial hemp stalk bale” from certain requirements and extend the validity of a hemp processor licence to three years.
27th February 2024: US - South Dakota: House Bill (HB) 1125 has been passed by the Senate. As the Senate amended the previously passed House version, the bill must be reconciled before being sent to the governor. HB 1125 would prohibit “chemically derived cannabinoids” – which are psychoactive cannabinoids that are changed molecularly through a chemical process (not including decarboxylation) – from being produced or sold in the state. The Senate has amended the bill to include that it would be unlawful to chemically modify or convert industrial hemp, or engage in any process that converts cannabidiol into delta-8 THC, delta-9 THC, delta-10 THC or any other THC isomer, analogue or derivative.
27th February 2024: US - South Dakota: Senate Bill (SB) 43 has been passed by the House and now heads to the governor’s desk. SB 43 would make minor amendments to the state's medical cannabis programme by requiring the department of health to establish certain penalties for violations of medical cannabis regulations and increasing the maximum amount that the department may charge for registration certificates.
23rd February 2024: US - South Dakota: Senate Bill (SB) 42 has been passed by the House and now heads to the governor’s desk. SB42 would make various amendments to the state’s medical cannabis programme. Amendments include changes to testing requirements, the allowable amount of medical cannabis that can be dispensed to qualified patients, and the procedure for violations of the medical cannabis regulations.
1st February 2024: US - South Dakota: House Bill (HB) 1125 has been passed by the House and now heads to the Senate. HB 1125 would prohibit "chemically derived cannabinoids", which are cannabinoids that are changed molecularly through a chemical process (not to include decarboxylation), from being produced or sold in the state.
23rd January 2024: US - South Dakota: The Senate has passed Senate Bill (SB) 43, which now moves to the House. SB 43 would make minor amendments to the state's medical cannabis programme by requiring the Department of Health to establish certain penalties for violations of medical cannabis regulations and increasing the maximum amount that the department may charge for registration certificates.
18th January 2024: US - South Dakota: Senate Bill (SB) 42 has been passed by the Senate and now heads to the House. SB 42 would make various amendments to the state's medical cannabis programme. Amendments include changes to testing requirements, the allowable amount of medical cannabis that can be dispensed to qualified patients, and the procedure for violations of the medical cannabis regulations.

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis

LATEST ALERTS

Cannabis and cannabinoids in South Dakota

News analysis

Future looks promising for US state-level legalisation despite midterm setback

Coming together over cannabis: is support becoming a bipartisan issue?

South Dakota in the US passes legislation making delta-8 THC legal for adult use

So it’s farewell to 2021 – a year that promised little and delivered less

Top South Dakota court overturns ballot bid to legalise recreational cannabis

Alerts

Regulatory reports

2022 US cannabis ballot initiative tracker

Which US states allow the sale of intoxicating hemp-derived cannabinoids in dispensaries?

US regulatory trends on intoxicating hemp-derived cannabinoids

US medical cannabis products: a state-by-state regulatory report

Regulatory report: US state-by-state taxation of medical cannabis

Regulatory databases

US regulatory tracker: state regulation of delta-8 THC, January

US regulatory tracker: proposed state laws, January

Sign up to our newsletter